Skip to main content
Log in

Brèves de l’AERIO

AERIO News in brief

  • Revue de Presse de l’AERIO/AERIO Press Review
  • Published:
Oncologie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. De Bono JS, Logothetis CJ, Molina A, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005

    Article  PubMed Central  PubMed  Google Scholar 

  2. Loriot Y, Bianchini D, Ileana E, et al. (2013) Antitumor activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7): 1807–1812

    Article  CAS  PubMed  Google Scholar 

  3. Noonan KL, North S, Bitting L, et al. (2013) Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24(7): 1802–1807

    Article  CAS  PubMed  Google Scholar 

  4. Scher HI, Fizazi K, Saad F, et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187–1197

    Article  CAS  PubMed  Google Scholar 

Références

  1. du Bois A, Lück HJ, Meier W, et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17): 1320–1329

    Article  PubMed  Google Scholar 

  2. Katsumata N, Yasuda M, Takahashi F, et al. (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698): 1331–1338

    Article  CAS  PubMed  Google Scholar 

  3. Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6(Suppl 3): 30–35

    Article  CAS  PubMed  Google Scholar 

  4. Ozols RF, Bundy BN, Greer BE, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17): 3194–3200

    Article  CAS  PubMed  Google Scholar 

  5. Pignata S, Scambia G, Lauria R, et al. (2013) A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. J Clin Oncol 31(Suppl; abstr LBA5501)

Références

  1. Perez A, Neskey DM, Wen J, et al. (2012) Abstract 2521: targeting CD44 in head and neck squamous cell carcinoma (HNSCC) with a new humanized antibody RO5429083. Cancer Res 72: 22521. doi: 10.1158/1538-7445.AM2012-2521

    Google Scholar 

  2. Seluanov A, Hine C, Azpurua J, et al. (2009) Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proc Natl Acad Sci U S A 106: 19352–19357. doi: 10.1073/pnas.0905252106

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

About this article

Cite this article

Brèves de l’AERIO. Oncologie 15, 543–547 (2013). https://doi.org/10.1007/s10269-013-2335-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-013-2335-1

Navigation